NCT05889221View on ClinicalTrials.gov

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

NAActive, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Multiple MyelomaMyeloma MultipleMyeloma
Interventions
OTHER

Drug and medical device

Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.

Trial Locations (1)

86000

CHU Poitiers, Poitiers

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Intergroupe Francophone du Myelome

NETWORK

lead

Poitiers University Hospital

OTHER

NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | Biotech Hunter | Biotech Hunter